SmarterDx — an AI startup that provides clinical review and quality audits for medical claims — closed a $50 million Series B funding round, bringing its total funding to date to $71 million.
HealthSnap closed a $25 million Series B funding round led by Sands Capital. The Miami-based company seeks to help providers better care for a rapidly aging and chronically ill population through its remote patient monitoring platform.
The TSX Venture Exchange has a strong history of helping early-stage health and life sciences companies raise patient capital for research and development.
Turquoise Health closed a $30 million Series B round, which brings its total funding to date to $55 million. The San Diego-based startup, which has more than 160 customers, sells a platform that makes it easier for hospitals and payers to comply with price transparency regulations.
Armed with fresh capital, Nava Benefits hopes to take advantage of what it believes will be a disruption in the way smaller businesses approach health and wellness benefits, including the many digital tools now on the market.
Notable CEO Matthew De Silva said the company has been able to successfully replicate its automated system, allowing for the export of the company's technology and growth of its commercial use cases.
VirtualHealth founder and CEO Adam Sabloff said the company is not disclosing the dollar amount of the round at this time but noted that the financing round brings the total amount raised by VirtualHealth to more than $25 million.
In an era of escalating healthcare costs and a growing preference for natural, holistic approaches to health, The Impact Brands emerges as a collective of diverse brands dedicated to supporting overall wellness through natural means.
GreatPoint Ventures led the Series B round for the San Francisco-based startup, and Tarsadia Investments, Crosslink Capital and Uncork Capital also participated.
Polaris Partners led the Series B round, and Ignition Partners, Osage University Partners, Mindset Ventures and UL Ventures also participated.
Black Granite Capital led the round, which the company, Jump Technologies, will use to expand its sales efforts and support product development.
The startup will use the money from Insight Venture Partners and Atomico for R&D, to further expand its reach in the MSK field and to grow its commercial team.
At the Payer Insights sessions on Day 1 of ViVE 2024, a panel on prior authorization offered compelling insights from speakers who shared the positive developments in this area after years of mounting frustration. Speakers also shared challenges as they work with providers to figure out how policy developments and technology will work in practice.
The Series B round, which Innovaccer will use to continue developing its InData platform, was led by Westbridge Capital. Lightspeed Ventures also participated.
Baltimore, Maryland-based startup Protenus has raised $11 million in a Series B round led by Kaiser Permanente Ventures and F-Prime Capital Partners. Arthur Ventures, LionBird Venture Capital and Cognosante Ventures also participated.
This one’s a hair better than, ah, the hair of the dog: Aldea Pharmaceuticals’ drug for acute alcohol intoxication is advancing into clinical trials, thanks to a sizable new round of funding. The new drug’s meant to be intravenously administered to emergency room patients with alcohol poisoning. The company just closed out a $24 million Series […]
The burgeoning cancer immunotherapy space has tons of investors, to be sure, but perhaps no other startup has ever been as well-capitalized as Seattle-based Juno Therapeutics. The company now has raised $310 million in the past year, having just closed a $134 million Series B round that comes right on the heels of its $176 million […]
Thermalin Diabetes is picking up steam – and funding – as it develops a more concentrated and faster-acting version of insulin. The Boston and Cleveland-based company just raised $5.9 million from private investors in the first tranche of a Series B round. To date, it has raised about $15 million in equity and $8 million in NIH […]